ABVC BioPharma, Inc. (NASDAQ: ABVC) has reported a transformative fiscal year 2025, with total assets surging 179% to $21.06 million, up from $7.54 million in 2024, according to its recently filed Annual Report on Form 10-K. The substantial growth was primarily fueled by strategic land acquisitions in Taiwan, as the company pivots toward an asset-backed licensing model that separates development risk from long-term value participation.
Net property and equipment rose sharply to $12.84 million from $511,088 in the prior year, driven by the acquisition of two significant parcels of land in Taiwan. The first, a 5,995.41 square meter property in Longtan District, Taoyuan, was valued at $4.6 million as of December 31, 2025. The second, a 69,230.90 square meter site in Puli Township, Nantou, was independently appraised at approximately $8.0 million as of January 30, 2026. The company is adopting a disciplined "land-first, development-later" approach, preserving strategic optionality for future healthcare-related applications, demonstration facilities, or supportive infrastructure aligned with biotechnology and long-term care initiatives.
Management believes the 2025 fiscal year represents a structural strengthening of the company's balance sheet and asset foundation. As of December 31, 2025, ABVC also reported operating lease right-of-use assets of $1.91 million and long-term investments of $1.88 million.
Central to ABVC's strategy is its licensing structure, which transfers development risk to subsidiaries and related parties while retaining economic benefits. Over prior years, the company licensed its core drug programs: the CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. Under this model, subsidiaries handle clinical development, reducing ABVC's direct cash burn, while the company retains licensing economics and equity participation. "Thus far, this model has enabled ABVC to separate development risk from long-term value participation, while preserving upside and mitigating capital intensity," the company stated.
The Puli site in Nantou is designed as a staged, long-term initiative focusing on establishing a medicinal plant cultivation base, supporting pharmaceutical supply chain localization, creating an agricultural-biotech integration platform, and developing value-added processing and storage infrastructure. Projected annual cultivation and processing output value is estimated between approximately $60,000 and $360,000, depending on processing depth. The title transfers for both properties are under government review in Taiwan, with final holding structures subject to regulatory requirements.
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the company intends to conduct pivotal clinical trials through global partnerships.
Forward-looking statements in the press release are subject to risks and uncertainties detailed in the company's filings with the SEC, available at http://www.sec.gov. The company assumes no obligation to update forward-looking statements.
